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The aim of the study was to assess the expression of the immune checkpoint inhibitor 21 
programmed death-ligand 1 (PD-L1) in equine sarcoids (ES). PD-L1 is expressed by various 22 
cancer cells to block T cell-mediated elimination of tumor cells. 23 
Antibodies targeting human PD-L1 were tested by immunohistochemistry (IHC) for their 24 
cross-reactivity with equine PD-L1 using formalin-fxed, paraffin-embedded (FFPE) tissues.  25 
Our results do not support an important role of PD-L1-mediated immune evasion in ES 26 
disease, and hence do not offer a rationale for anti-PD-1/PD-L1-based immunotherapy against 27 
ES.  28 
Keywords: Equine sarcoids, immune checkpoint inhibition, immune evasion, 29 
immunohistochemistry, PD-L1  30 
1. Introduction 31 
Equine sarcoids (ES) are the most common tumors in equids and account for more than half 32 
of all skin tumors in this species [1,2]. Treatment is often challenging due to the notoriously 33 
high propensity for tumor recurrence [3], the lack of tissue-sparing treatment options and 34 
effective systemic or prophylactic treatment modalities. 35 
In human medical oncology, a novel therapeutic approach has recently achieved remarkable 36 
successes: targeting of the immune checkpoint inhibitor programmed death-ligand 1 (PD-L1) 37 
or programmed cell death protein 1 (PD-1) [4,5]. It has resulted in tumor eradication in cancer 38 
patients previously thought to be incurable (e.g. advanced melanoma or lung cancer). 39 
The physiologic role of immune checkpoints is to maintain self-tolerance and protect tissues 40 
from self-damage, for instance while responding to an infection [6–8]. The dysregulation of 41 
these immune checkpoint proteins can be observed in various cancers, and represents an 42 
important mechanism for tumor cells to evade the immune system [6,9]. PD-L1 is expressed 43 
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by various cancer cells to block T cell-mediated elimination of the tumor cells by binding to 44 
programmed cell death protein 1 (PD-1) at the surface of T lymphocytes. This mechanism of 45 
immune evasion can be prevented by using specific ant bodies against PD-L1 or PD-1 [6]. 46 
The aim of this study was to establish an immunohist chemistry (IHC) staining protocol to 47 
assess PD-L1 expression in ES-derived and other equine tissue samples. As an additional 48 
control to investigate the cross-reactivity of the antibody for equine PD-L1, we also tested 49 
mandibular lymph node as lymph nodal tissue has been d scribed to contain immune cells 50 
expressing PD-L1 in humans [10]. 51 
We hypothesized that (transformed) equine fibroblasts derived from ES tumors express PD-52 
L1. Substantial expression would support PD-L1 as a mechanism of immune evasion in ES 53 
disease and consequently, immunotherapy directed against PD-L1 would be a reasonable 54 
approach for the treatment of ES tumors. 55 
2. Material and Methods 56 
Lesional tissue samples from ten horses presented for surgical removal of histologically 57 
confirmed ES tumors were investigated. Samples were obtained from seven geldings, two 58 
mares and one stallion of different breeds (one Shetland pony, one Rocky mountain horse, 59 
one American Quarter horse, one Arabian, one Friesian, one Swiss Warmblood, one 60 
Franches-Montagnes and one mixed breed) and included ES tumors of different gross 61 
morphology (three fibroblastic, four verrucous, two n dular and one mixed). These samples 62 
were retrieved from the ISME (Swiss Institue of Equine Medicine) tumor tissue bank. 63 
Samples of equine placenta from a Franches-Montagnes mare and samples of an equine 64 
mandibular lymph node from a Selle-Français mare were collected from patients of the ISME. 65 
All owner gave their informed written consent.  66 
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PD-L1 is expressed at the surface of villous syncytiotrophoblasts and cytotrophoblasts of the 67 
placenta to confer the fetomaternal tolerance [11]. Human placenta tissue samples, used as 68 
positive control, were obtained from the Translational Research Unit (TRU) of the University 69 
of Bern.  70 
A rabbit polyclonal antibody (orb158130, Biorbyt, UK) was used, which reacts with human 71 
and mouse PD-L1, and is predicted to cross-react with the horse antigen. Comparison of the 72 
equine PD-L1 amino acid sequence using BLAST (https://blast.ncbi.nlm.nih.gov) revealed an 73 
80% homology to human PD-L1.  74 
As a positive control for the IHC protocol on FFPE slides the cytokeratine AE1/AE3 antibody 75 
(monoclonal mouse α-human, Dako, M3515) was used at a dilution of 1:50. Negative controls 76 
were created by omitting the primary antibodies. 77 
Four-µm FFPE tumor sections were dried on silane-coated slides. The slides were 78 
subsequently deparaffinizaded and re-hydrated. Antige  retrieval was performed in citrate 79 
buffer (pH 6.0), by boiling for 10 minutes in the microwave oven. Endogenous peroxidase 80 
activity was blocked with 3% hydrogen peroxide for 30 minutes. Bovine serum albumin, also 81 
at a concentration of 3%, was subsequently added. The primary antibody (orb158130, 82 
Biorbyt, dilution 1:200, incubation at room temperatu e) was applied overnight. The 83 
secondary biotinylated antibody (Dako, K0675) + System HRP (Dako, K0675) were added. 84 
Between every step the slides were washed in 0,05% Tween Tris-buffered saline 85 
(TBS/Tween) solution at pH 7.6 (Dako, S3006). DAB (3,3‘-diaminobenzidine 86 
tetrahydrochloride) was used for the staining. In a fin l step, slides were counterstained with 87 
hematoxylin. IHC protocol is shown in detail in Table 1. 88 
The stained slides were assessed by a board-certified pathologist (SR) using light microscopy, 89 
inspecting the sections with x4, x10, x20 and x40 objectives. A semiquantitative scoring 90 
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system was applied for the assessment of cell staining. A positive cell was defined as a cell 91 
exhibiting a membranous signal alone or a membranous and cytoplasmatic signal. The 92 
following scoring system was used: grade 0: 0%, grade 1: <10%, grade 2:10-25%, grade 3: 93 
25-50%, and grade 4: >50% of cells staining positive for PD-L1. 94 
3. Results 95 
Positive (cytokeratin-staining) and negative controls (primary antibody omitted) yielded 96 
expected results, thus highlighting the technical acuracy of the experiment (data not shown). 97 
PD-L1-staining of equine placental tissue yielded a membrane and a cytoplasmic signal 98 
(Figure 1), consistent with the staining of the human placenta samples. Although the signal 99 
was somewhat weaker than on the human placenta, the result suggests that the orb158130 100 
antibody does detect PD-L1 in horses. This result was corroborated in the horse lymph node, 101 
showing a few clearly positive cells, especially in the area of lymph follicle but also in others 102 
areas. The signal was mainly granular and localized n the membrane and the cytoplasm. In 103 
7/9 examined ES tumors, less than 10% of the tumor cells exhibited a positive signal. Only in 104 
2/9 ES tumors 25-50% of the cells showed a positive signal for PD-L1 (score 3+). The results 105 
are summarized in Table 2. 106 
4. Discussion 107 
Based on the findings of this study, ES-derived, transformed equine fibroblasts do not appear 108 
to consistently express PD-L1. In fact, most of the cells of the analyzed ES tumors stained 109 
negative for the protein PD-L1. In 7/9 of the examined ES tumor samples, less than 10% of 110 
the tumor cells tested positive for PD-L1 expression. In contrast, cells in equine and human 111 
placental samples consistently expressed PD-L1. Similarly, cells in lymph tissue showed a 112 
granular membranous and cytoplasmic signal.  113 
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Although the number of examined tumors is low, thispilot experiment suggests that PD-L1 is 114 
not generally expressed by ES-derived transformed equin  fibroblasts and therefore PD-1 115 
blockade is unlikely a general mechanism of immune evasion in ES disease. However, PD-L1 116 
is not only expressed by tumor cells but also by T- and B-lymphocytes and dendritic cells that 117 
infiltrate the tumor microenvironment [12]. Reportedly, the predominant immune cell 118 
populations which infiltrate ES tissues are macrophages and monocytes [13], but also T-cells 119 
[14]. In our study, we focused on the quantification of PD-L1-positive transformed fibroblasts 120 
that are readily differentiated from immune cells, based on morphological criteria. As a small 121 
percentage of immune cells was also PD-L1-positive, it would be interesting to characterize 122 
the precise nature of these immune cells in ES in the future. 123 
In human medicine, overexpression of PD-L1 has been observed in some cancers, including 124 
melanomas [15]. Three equine melanomas were included in the study an  in two lesions about 125 
30-50% of tumor cells stained positive for PD-L1. In this study, human placenta delivered at 126 
birth was used as a positive control. In human placentas the expression of PD-L1 is highest in 127 
the second and third trimester of pregnancy [16]. In equine placenta, endometrial cups are 128 
present in the uterine wall from day 40 and up to day 150 of gestation, but regress after day 129 
70. Given the particular role of endometrial cups in the development of the fetal immune 130 
system, staining of the epithelium of endometrial cups may differ in earlier gestation stages in 131 
equids compared to humans. 132 
The similarities in the PD-L1 staining pattern betwen human and equine positive control 133 
tissues found in this comparative analysis suggest that the antibody used in the described 134 
protocol is indeed valid for PD-L1 detection in equine tissues, albeit it is not an unequivocal 135 
proof for PD-L1-specificity of the antibody in the horse. As equine keratinocytes also stained 136 
positive in five out of nine slides with ES-derived tissues, unspecific cross-reactivity of the 137 
antibody cannot be ruled out and is the most likely xplanation for this observation. 138 
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Alternatively, BPV-DNA may more consistently lead to the expression of PD-L1 in infected 139 
equine keratinocytes compared to BPV-transformed equin  fibroblasts. Whereas BPV 140 
completes an infectious life-cycle within the epidermal keratinocytes of its natural bovine host 141 
and leading to the production of countless infectious virions [17], the BPV-infection in the 142 
equine host is generally considered "non-productive" or "abortive" [18,19]. More recently, 143 
however, BPV-DNA has also been detected in keratinocytes of ES tissues [20], albeit at much 144 
lower levels compared to those found in BPV-transformed equine fibroblasts. Nonetheless, 145 
these findings combined with reports of ES disease-transmission in the absence of a bovine 146 
source for BPV [21] give reason to belief that the BPV-infection in ES-affected horses may 147 
not be entirely "abortive". Likewise, it may be speculated that a BPV-infection may induce 148 
PD-L1 expression in equine keratinocytes but not in fibroblasts. Thus, this would be an 149 
explanation for the positive staining for PD-L1 of keratinocytes associated with ES-lesions, in 150 
the absence of positive staining of fibroblasts, as observed in this study. 151 
Ideally, the specificity of an antibody should be tested in isogenic cell lines or tissues 152 
containing a wild-type and a knockout of the gene of interest. Using CRISPR-cas9 technology 153 
it would be possible to induce Pd-l1 knockouts in cultured cells that normally express thi154 
receptor and thereby generate such controls. Another approach would be the expression of the 155 
equine Pd-l1 cDNA in cells that are PD-L1 negative. However, a disadvantage of this 156 
approach is that non-physiologically high expression levels are reached and that it remains 157 
unclear whether the antibody detects physiologically relevant protein levels. 158 
While our results do not support PD-L1 as a potential therapeutic target, it is not the only 159 
protein able to downregulate the immune response. Many immunosuppressive mechanisms 160 
have been documented in the tumor microenvironment, including the recruitment of 161 
regulatory T cells (Tregs) [22] or myeloid derived suppressor cells (MDSC) [23], production 162 
of IL-10 [24] and TGFβ [25] or expression of other immune checkpoint regulators, such as 163 
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CTLA-4 (cytotoxic T lymphocyte antigen) [26,27]. In this study, we focused on PD-L1, but 164 
further studies are needed to evaluate potential mechanisms of immune evasion and the 165 
presence of other negative regulatory molecules in the microenvironment of ES tumors. 166 
5. Conclusion 167 
In this experiment, we observed positive PD-L1 staining in equine placental and lymph 168 
follicle cells, but only in low numbers of ES-derived equine fibroblasts. This suggests that this 169 
PD-L1 is not regularly expressed in ES and PD-L1 blockade does not serve as an important 170 
mechanism of immune evasion in this form of neoplasia. However, these findings need to be 171 
confirmed in a greater number of samples and using antibodies that are more thoroughly 172 
validated for applications in equine-derived tissues. Nonetheless, PD-L1 is not only expressed 173 
by tumor cells but also by immune cells that infiltrate the tumor microenvironment, and  174 
future research may reveal the precise nature of the immune cells within ES tissues that 175 
express PD-L1 and unravel their role in ES disease. Finally yet importantly, preliminary 176 
results obtained on equine melanomas indicate the pot ntial of a targeted therapy of this 177 
tumor type with anti-PD-L1 antibodies. 178 
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Tables 274 
Table 1: Immunohistochemistry protocol used in the study 275 
Deparaffination and Hybridation   
Melting paraffin in the oven at 60°C 
Xylol  
Xylol  
Ethanol 100% 
Ethanol 100% 
Ethanol 95% 
Ethanol 70% 
Distilled water  
 10min 
 10min 
 10min 
 2min 
 2min 
 2min 
 2min 
 2min 
Antigen- Retrieval  
10mM Citrate Buffer pH 6.0 
Room temperature cooling 
Distilled water 
 10min boiling in microwave 
 5min 
 2x 5min  
Endogenous peroxidase block  
H2O2 3% (in water) 
Distilled water  
Wash with Dako washing buffer (S3006) 
 20min 
 2x 5min  
 5min 
Biotin blot  
Block endogenous protein with bovine 
serum albumin 3% (BSA) in PBS  
Wash with Dako washing buffer (S3006) 
 30min 
 
 2x5min 
Primary antibody   
PD-L1 in Ab diluent (S0809, Dako) 
Wash with Dako washing buffer (S3006) 
 Dilution 1 :200, overnight incubation 
 3x5min 
Secondary antibody   
Universal secondary antibody (K0675, 
Dako) 
Wash with Dako washing buffer (S3006) 
 
HRP-conjugat streptavidin (K0675, Dako) 
 
Wash with Dako washing buffer (S3006) 
 
DAB  
 
Distilled water 
Hematoxylin couterstain 
Running tap water  
Distilled water 
Mounting  
 30min 
 3x5min 
 
 30min 
 
 3x5min 
 
 4min 
 
 5min 
 Few seconds  
 5min  
 5min  
 276 
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Table 2: Summary of the number of slides per score. One equin  sarcoid was excluded of the 278 
study because most of the tissue was destroyed after the immunohistochemistry procedure. 279 
 280 
Score  0  1+  2+  3+  4+  
Human placenta          1  
Equine placenta          1  
Lymph node    1        
Equine Sarcoids            
• Verrucous   1  1    1    
• Nodular    2        
• Fibroblastic  1  1    1    
• Mixed (verrucous 
and fibroblastic)  1          
 281 
  282 
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Figure 283 
284 
Figure 1: Equine sarcoid, negative (no programmed death-ligand 1 staining) and positive 285 
controls. Note that the signal is consistently weaker in equine tissues compared to human 286 
tissues. 287 
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Highlights 
 
• Establishment of an IHC protocol for equine PD-L1 using FFPE material 
• Preliminary finding indicate that equine sarcoid-derived tissues do not frequently express PD-
L1  
• The low expression levels of PD-L1 in equine sarcoid-derived tissues argue against PD-L1 
contribution to immune evasion in this neoplastic disease 
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